Inhibitor-induced HER2-HER3 heterodimerisation promotes proliferation through a novel dimer interface

Inhibitor-induced HER2-HER3 heterodimerisation promotes proliferation through a novel dimer interface

While targeted therapy against HER2 is an effective first-line treatment in HER2+ breast cancer, acquired resistance remains a clinical challenge. The pseudokinase HER3, heterodimerisation partner of HER2, is widely implicated in the resistance to HER2-mediated therapy. Here, we show that lapatinib,...

Full description

Bibliographic Details
Main Authors: Jeroen Claus, Gargi Patel, Flavia Autore, Audrey Colomba, Gregory Weitsman, Tanya N Soliman, Selene Roberts, Laura C Zanetti-Domingues, Michael Hirsch, Francesca Collu, Roger George, Elena Ortiz-Zapater, Paul R Barber, Boris Vojnovic, Yosef Yarden, Marisa L Martin-Fernandez, Angus Cameron, Franca Fraternali, Tony Ng, Peter J Parker
Format: Article
Language:English
Published: eLife Sciences Publications Ltd 2018-05-01
Series:eLife
Subjects:
HER2
HER3
protein kinase
pseudokinase
kinase inhibitors
lapatinib
Online Access:https://elifesciences.org/articles/32271

Internet

https://elifesciences.org/articles/32271

Similar Items